IMR — Imricor Medical Systems Income Statement
0.000.00%
- AU$428.23m
- AU$435.07m
- $0.96m
Annual income statement for Imricor Medical Systems, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.702 | 0.696 | 0.816 | 0.616 | 0.959 |
Cost of Revenue | |||||
Gross Profit | -0.398 | -1.9 | -1.53 | -1.12 | -0.924 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 12.7 | 21 | 18.1 | 17.5 | 17.3 |
Operating Profit | -12 | -20.3 | -17.3 | -16.9 | -16.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.4 | -19.7 | -17.4 | -22.6 | -29.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.4 | -19.7 | -17.4 | -22.6 | -29.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.4 | -19.7 | -17.4 | -22.6 | -29.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.4 | -19.7 | -17.4 | -22.6 | -29.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.113 | -0.146 | -0.115 | -0.144 | -0.133 |